Podcast Episodes
Back to Search
Ep. 349 - Start-up Spotlight, Compounding Wegovy & Neuropysch
Season 7 Episode 349
2025 marked the end of a four-year slide in series A financings for biotechs, with 144 biotechs raising an aggregate of $8 billion, up $1 billion fro…
9 months, 1 week ago
Ep. 348 - Biotech's 2026 Catalysts. Plus: China's New Orphan Rules
Season 7 Episode 348
RNAi and exon-skipping therapies headline the list of regulatory and pivotal data catalysts in 2026, while new lipid-lowering mechanisms, modalities,…
9 months, 2 weeks ago
Ep. 347 - Speeding China's Innovation. Plus: Neuro Catalysts and Newcos
Season 7 Episode 347
New rules in China will accelerate the country’s cell and gene therapy sector by reshaping how investigator-initiated trials are conducted and commer…
9 months, 3 weeks ago
Ep. 346 - 2026 Public Markets Preview
Season 7 Episode 346
The biotech bull is back, and buysiders believe this market has staying power for the first time in nearly five years. On a special episode of the Bi…
9 months, 4 weeks ago
Ep. 345 - TAC to the Future. Plus: GSK Deal, MFN
Season 7 Episode 345
Next-generation induced proximity technologies are coming of age after a decade of industry focus on PROTACs. On the latest BioCentury This Week podc…
10 months ago
Ep. 344 - JPM Momentum and Asia’s Hotbeds of Innovation
Season 7 Episode 344
The J.P. Morgan Healthcare Conference kicked off this week with sunny skies over San Francisco and more financial momentum than the biotech industry …
10 months ago
Ep. 343 - JPM Deals, Policy Outlook, Approval Trends
Season 7 Episode 343
Riding the tailwind of a strong 2H25, the days leading up to biotech’s annual kickoff meeting in San Francisco delivered billions in capital raised a…
10 months, 1 week ago
Ep. 342 - 2026 Biotech Kickoff
Season 7 Episode 342
The New Year begins with biotech running along parallel storylines. There’s cause for optimism as the industry’s financing gears have begun to churn …
10 months, 2 weeks ago
Ep. 341 - BioCentury's '25-'26 Picks. Plus: BioMarin & Biotech ICYMI
Season 6 Episode 341
This past year was an inflection point for biotech: The markets woke up, M&A and China had strong showings, drug development offered key trends, and …
10 months, 3 weeks ago
Ep. 340 - Obesity Data, Kymera & FDA Survey Results
Season 6 Episode 340
Obesity readouts continue to be hot for biotech with new top-line data from both injectable and oral therapies pushing the boundaries on efficacy. On…
11 months ago